Geode Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $562K | Buy |
172,255
+37,598
| +28% | +$123K | ﹤0.01% | 3518 |
|
|
2025
Q1 | $276K | Buy |
134,657
+60,406
| +81% | +$124K | ﹤0.01% | 3747 |
|
|
2024
Q4 | $163K | Sell |
74,251
-3,090
| -4% | -$6.8K | ﹤0.01% | 3961 |
|
|
2024
Q3 | $131K | Buy |
77,341
+11,682
| +18% | +$19.7K | ﹤0.01% | 4033 |
|
|
2024
Q2 | $160K | Buy |
65,659
+23,664
| +56% | +$57.8K | ﹤0.01% | 3991 |
|
|
2024
Q1 | $198K | Buy |
41,995
+803
| +2% | +$3.79K | ﹤0.01% | 3944 |
|
|
2023
Q4 | $190K | Hold |
41,192
| – | – | ﹤0.01% | 3962 |
|
|
2023
Q3 | $107K | Buy |
41,192
+3,325
| +9% | +$8.65K | ﹤0.01% | 4225 |
|
|
2023
Q2 | $183K | Hold |
37,867
| – | – | ﹤0.01% | 4080 |
|
|
2023
Q1 | $250K | Hold |
37,867
| – | – | ﹤0.01% | 3937 |
|
|
2022
Q4 | $420K | Buy |
37,867
+5,804
| +18% | +$64.4K | ﹤0.01% | 3741 |
|
|
2022
Q3 | $237K | Buy |
32,063
+1,220
| +4% | +$9.02K | ﹤0.01% | 4107 |
|
|
2022
Q2 | $185K | Buy |
30,843
+1,456
| +5% | +$8.73K | ﹤0.01% | 4316 |
|
|
2022
Q1 | $719K | Buy |
29,387
+8,237
| +39% | +$202K | ﹤0.01% | 3764 |
|
|
2021
Q4 | $1.01M | Buy |
21,150
+16,573
| +362% | +$791K | ﹤0.01% | 3717 |
|
|
2021
Q3 | $424K | Buy |
4,577
+1,129
| +33% | +$105K | ﹤0.01% | 4107 |
|
|
2021
Q2 | $400K | Buy |
+3,448
| New | +$400K | ﹤0.01% | 4040 |
|